argenx halts Phase 3 Sjögren's disease trial after futility finding

argenx has halted its Phase 3 Sjögren's disease trial after a futility finding, according to an unconfirmed report. The stock is down 13% in pre-market trading.

Detected & updated continuously · Source: Nebula